Cancer is one of the leading causes of death worldwide. According to the latest report of WHO, cancer accounts for nearly one in six deaths. Antibody-drug conjugates (ADCs) are a relatively new class of anticancer drugs with high specificity and potent killing properties. ADCs consist of three key components: a monoclonal antibody, a linker, and a payload. When the specific antibody targets the surface antigen of tumor cells, ADCs are internalized and processed by the endo-lysosomal system to release the potent cytotoxic drug. However, antibodies may exhibit low internalization efficiency upon binding to the cell surface, resulting in inefficient internalization of ADCs and insufficient release of payloads. Indeed, internalization efficiency is a key mechanism underlying ADCs that impacts therapeutic efficacy.
Through this talk, we aim to discuss internalization assay systems and provide a simple and convenient tool - recombinant protein DT3C - to facilitate the comparison of the internalization efficiency of monoclonal antibodies, as well as the clinical development of ADCs for cancer treatment.
1. Overview of the development of antibody and antibody-drug conjugates (ADCs)
2. A brief introduction of internalization assay systems in ADCs development
3. Advantages of recombinant protein DT3C in antibody internalization analysis
March 6th | 3 PM EST (8 PM GMT)
Ying Zhou PhD
Product Manager, CUSABIO
Dr. Ying Zhou is a Product Manager at CUSABIO, responsible for product marketing, development, and optimization. Before joining CUSABIO, Dr. Zhou earned her Ph.D. in Biology and Biotechnology from Worcester Polytechnic Institute in the United States. Following her graduation, she pursued post-doctoral training at the University of California, Davis. Dr. Zhou's expertise lies in molecular biology and protein science, specifically in mRNA expression and regulation. She is particularly interested in mRNA stability and RNA-interacting proteins.